Top

Published in:

01-01-2018 | Original Article

New pulmonary hypertension model in conscious dogs to investigate pulmonary-selectivity of acute pharmacological interventions

Authors: Thomas Mondritzki, Philip Boehme, Lena Schramm, Julia Vogel, Ilka Mathar, Peter Ellinghaus, Peter Kolkhof, Erwin Bischoff, Jörg Hüser, Wilfried Dinh, Peter Sandner, Hubert Truebel

Published in: European Journal of Applied Physiology | Issue 1/2018

Abstract

Purpose

Testing of investigational drugs in animal models is a critical step in drug development. Current models of pulmonary hypertension (PH) have limitations. The most relevant outcome parameters such as pulmonary artery pressure (PAP) are measured invasively which requires anesthesia of the animal. We developed a new canine PH model in which pulmonary vasodilators can be characterized in conscious dogs and lung selectivity can be assessed non-invasively.

Methods

Telemetry devices were implanted to measure relevant hemodynamic parameters in conscious dogs. A hypoxic chamber was constructed in which the animals were placed in a conscious state. By reducing the inspired oxygen fraction (FiO₂) to 10%, a hypoxic pulmonary vasoconstriction was induced leading to PH. The PDE-5 inhibitor sildenafil, the current standard of care was compared to atrial natriuretic peptide (ANP).

Results

The new hypoxic chamber provided a stable hypoxic atmosphere during all experiments. The mean PAP under normoxic conditions was 15.8 ± 1.8 mmHg. Hypoxia caused a reliable increase in mean PAP (+ 12.2 ± 3.2 mmHg, p < 0.0001). Both, sildenafil (− 6.8 ± 4.4 mmHg) and ANP (− 6.4 ± 3.8 mmHg) significantly (p < 0.05) decreased PAP. Furthermore sildenafil and ANP showed similar effects on systemic hemodynamics. In subsequent studies, the in vitro effects and gene expression pattern of the two pathways were exemplified.

Conclusions

By combining the hypoxic environment with the telemetric approach, we could successfully establish a new acute PH model. Sildenafil and ANP demonstrated equal effects regarding pulmonary selectivity. This non-invasive model could help to rapidly screen pulmonary vasodilators with decreased animal burden.

Available only for authorised users

Anker SD, Ponikowski P, Mitrovic V, Peacock WF, Filippatos G (2015) Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies. Eur Heart J 36(12):715–723. https://doi.org/10.1093/eurheartj/ehu484 CrossRefPubMedPubMedCentral

de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H (1981) A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 28(1):89–94CrossRef

de Bold MK, Sheffield WP, Martinuk A, Bhakta V, Eltringham-Smith L, de Bold AJ (2012) Characterization of a long-acting recombinant human serum albumin-atrial natriuretic factor (ANF) expressed in Pichia pastoris. Regul Pept 175(1–3):7–10. https://doi.org/10.1016/j.regpep.2012.01.005 CrossRefPubMed

Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M (2015) 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 46(4):903–975. https://doi.org/10.1183/13993003.01032-2015 CrossRefPubMed

Ghofrani HA, Galie N, Grimminger F, Grunig E, Humbert M, Jing ZC, Keogh AM, Langleben D, Kilama MO, Fritsch A, Neuser D, Rubin LJ, Group P-S (2013) Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 369 (4):330–340. https://doi.org/10.1056/NEJMoa1209655 CrossRefPubMed

Goodchild C, Serrao J (1989) Cardiovascular effects of propofol in the anaesthetized dog. Br J Anaesth 63(1):87–92CrossRef

Handoko ML, Schalij I, Kramer K, Sebkhi A, Postmus PE, van der Laarse WJ, Paulus WJ, Vonk-Noordegraaf A (2008) A refined radio-telemetry technique to monitor right ventricle or pulmonary artery pressures in rats: a useful tool in pulmonary hypertension research. Pflugers Arch Eur J Physiol 455(5):951–959. https://doi.org/10.1007/s00424-007-0334-z CrossRef

Hohne C, Drzimalla M, Krebs MO, Boemke W, Kaczmarczyk G (2003) Atrial natriuretic peptide ameliorates hypoxic pulmonary vasoconstriction without influencing systemic circulation. J Physiol Pharmacol 54(4):497–510PubMed

Jin HK, Yang RH, Thornton RM, Chen YF, Jackson R, Oparil S (1988) Atrial natriuretic peptide lowers pulmonary arterial pressure in hypoxia-adapted rats. J Appl Physiol 65(4):1729–1735CrossRef

Lara-Pezzi E, Menasche P, Trouvin JH, Badimon L, Ioannidis JP, Wu JC, Hill JA, Koch WJ, De Felice AF, de Waele P, Steenwinckel V, Hajjar RJ, Zeiher AM (2015) Guidelines for translational research in heart failure. J Cardiovasc Transl Res 8(1):3–22. https://doi.org/10.1007/s12265-015-9606-8 CrossRefPubMed

Lawrie A (2014) A report on the use of animal models and phenotyping methods in pulmonary hypertension research. Pulm Circ 4(1):2–9. https://doi.org/10.1086/674886 CrossRefPubMedPubMedCentral

Liu LS, Cheng HY, Chin WJ, Jin HK, Oparil S (1989) Atrial natriuretic peptide lowers pulmonary arterial pressure in patients with high altitude disease. Am J Med Sci 298(6):397–401CrossRef

Maarman G, Lecour S, Butrous G, Thienemann F, Sliwa K (2013) A comprehensive review: the evolution of animal models in pulmonary hypertension research; are we there yet? Pulm Circ 3(4):739–756. https://doi.org/10.1086/674770 CrossRefPubMedPubMedCentral

McKie PM, Ichiki T, Burnett JC Jr (2012) M-atrial natriuretic peptide: a novel antihypertensive protein therapy. Curr Hypertens Rep 14(1):62–69. https://doi.org/10.1007/s11906-011-0244-5 CrossRefPubMed

McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J, American College of Cardiology Foundation Task Force on Expert Consensus D, American Heart A, American College of Chest P, American Thoracic Society I, Pulmonary Hypertension A (2009) ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 53 (17):1573–1619. https://doi.org/10.1016/j.jacc.2009.01.004 CrossRefPubMed

Mitaka C, Kudo T, Haraguchi G, Tomita M (2011) Cardiovascular and renal effects of carperitide and nesiritide in cardiovascular surgery patients: a systematic review and meta-analysis. Crit Care 15(5):R258. https://doi.org/10.1186/cc10519 CrossRefPubMedPubMedCentral

Morikawa S, Sone T, Tsuboi H, Mukawa H, Morishima I, Uesugi M, Morita Y, Numaguchi Y, Okumura K, Murohara T (2009) Renal protective effects and the prevention of contrast-induced nephropathy by atrial natriuretic peptide. J Am Coll Cardiol 53(12):1040–1046. https://doi.org/10.1016/j.jacc.2008.10.061 CrossRefPubMed

Preston IR, Hill NS, Gambardella LS, Warburton RR, Klinger JR (2004) Synergistic effects of ANP and sildenafil on cGMP levels and amelioration of acute hypoxic pulmonary hypertension. Exp Biol Med 229(9):920–925CrossRef

Saito Y (2010) Roles of atrial natriuretic peptide and its therapeutic use. J Cardiol 56(3):262–270. https://doi.org/10.1016/j.jjcc.2010.08.001 CrossRefPubMed

Schafer S, Ellinghaus P, Janssen W, Kramer F, Lustig K, Milting H, Kast R, Klein M (2009) Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling. Cardiovasc Res 82(1):30–39. https://doi.org/10.1093/cvr/cvp002 CrossRefPubMed

Sezai A, Hata M, Niino T, Yoshitake I, Unosawa S, Wakui S, Fujita K, Takayama T, Kasamaki Y, Hirayama A, Minami K (2010) Continuous low-dose infusion of human atrial natriuretic peptide in patients with left ventricular dysfunction undergoing coronary artery bypass grafting: the NU-HIT (Nihon University working group study of low-dose Human ANP Infusion Therapy during cardiac surgery) for left ventricular dysfunction. J Am Coll Cardiol 55(17):1844–1851. https://doi.org/10.1016/j.jacc.2009.11.085 CrossRefPubMed

Zakeri R, Burnett JC (2011) Designer natriuretic peptides: a vision for the future of heart failure therapeutics. Can J Physiol Pharmacol 89(8):593–601. https://doi.org/10.1139/y11-048 CrossRefPubMed

Title: New pulmonary hypertension model in conscious dogs to investigate pulmonary-selectivity of acute pharmacological interventions
Authors: Thomas Mondritzki
Philip Boehme
Lena Schramm
Julia Vogel
Ilka Mathar
Peter Ellinghaus
Peter Kolkhof
Erwin Bischoff
Jörg Hüser
Wilfried Dinh
Peter Sandner
Hubert Truebel
Publication date: 01-01-2018
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Applied Physiology / Issue 1/2018
Print ISSN: 1439-6319
Electronic ISSN: 1439-6327
DOI: https://doi.org/10.1007/s00421-017-3761-3

At a glance: The STEP trials

Springer Medicine

New pulmonary hypertension model in conscious dogs to investigate pulmonary-selectivity of acute pharmacological interventions

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

Classical experiments in whole-body metabolism: open-circuit respirometry—diluted flow chamber, hood, or facemask systems

A cross-sectional study on the mechanical properties of the Achilles tendon with growth

Heterogeneity of passive elastic properties within the quadriceps femoris muscle–tendon unit

Changes in fat oxidation in response to various regimes of high intensity interval training (HIIT)

Trunk proprioception adaptations to creep deformation

Thyroid hormones and commonly cited symptoms of overtraining in collegiate female endurance runners